Roche provides update on US FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory DLBCL: Basel Thursday, May 22, 2025, 12:00 Hrs [IST] Roche ...

For J&J, there was a positive outcome as the Oncologic Drugs Advisory Committee (ODAC) voted six to two in favour of approval ...

In a somber end to an FDA advisory committee’s two-day scouring of multiple drugmakers’ oncology data, Pfizer’s pitch to ...

The FDA is likely to approve the first treatment for smoldering multiple myeloma but pass on a new option relapsed/refractory DLBCL, after votes by its Oncologic Drugs Advisory Committee.